ITEMS IN AFP WITH KEYWORD:
If you are thinking about adding lung cancer screening to your delivery of preventive care, be sure to prepare patients. They are likely to receive a positive result, most of the positive results will not be lung cancer, and one in four patients will require additional tracking (i.e., follow-up scans).
A 50-year-old woman presents for a routine visit. She is healthy with no significant medical history, takes no medications, and has no personal or family history of cancer.
May 15, 2017 Issue
Should Screening Techniques for Colorectal Cancer All Have an 'A' Recommendation? No: When It Comes to Colorectal Cancer Screening, Test Choice Matters [Editorials: Controversies in Family Medicine]
The AAFP will continue to evaluate different screening tests as more research becomes available, but currently can endorse only those options that have the strongest evidence that benefits exceed harms.
May 15, 2017 Issue
Should Screening Techniques for Colorectal Cancer All Have an 'A' Recommendation? Yes: All Conventional Screening Techniques Should Have an 'A' Recommendation [Editorials: Controversies in Family Medicine]
We need to emphasize the message that regardless of which test is used, patients should get screened for colorectal cancer.
Feb 15, 2017 Issue
Screening for Colorectal Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
For family physicians to put PSA screening guidance into practice, they must elicit patients' preferences and provide accurate, understandable information about the benefits and harms.
S.O. is a 47-year-old woman who presents to your office for a well-woman visit. She is healthy, takes no medications, and has no health concerns. She has never been diagnosed with breast cancer, nor have any of her first-degree relatives. Her digital mammography two years ago was negative, and she a...
Based on the initial round of screening in this randomized trial, it appears that more patients complete fecal immunochemical testing than colonography or colonoscopy. Using the most conservative estimate, the yields of advanced adenomas and advanced neoplasms are similar.
In keeping with the principles of the Choosing Wisely campaign, physicians and patients would do well to avoid the pitfalls of overscreening and wait for results that promise more hope than hype.
An overview of the recent results from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and implications for clinical practice and public health.